Last updated: 2026-10-01 09:11:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Ensysce Biosciences, Inc. (ENSC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.42, with a market capitalization of $8.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.23 to $2.75. This page covers its latest market performance, valuation, price trends and company information.
$8.11M | |
$0.42 | |
$61,632.00 | |
$0.23 | |
$0.42 | |
3.59K | |
14.42M | |
-- | |
$2.75 | |
$0.23 | |
-- | |
-- |
Ensysce Biosciences, Inc. (ENSC) is trading at $0.42 in pre-market trading as of 2026-10-01 08:33:00, down 0.19% ($0.00) from the previous close of $0.42
Pre-market trading shows how investors are pricing ENSC before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Ensysce Biosciences, Inc. (ENSC) moved from $0.43 to $0.42, representing a decline of 3.26% ($0.01).
The stock traded between $0.40 and $0.44 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 251.69 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.3%
ENSC is currently trading at $0.42, placing it 7.3% of the way from its 52-week low of $0.23 to its 52-week high of $2.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ensysce Biosciences, Inc. (ENSC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.